Browse

- Presentation
- Article
- Survey
- Quiz
- Lead-form
- E-Book
Pro
Upload

Content Directory

Content Directory
t
t-rv-nyi-szab-ly -> table-of-content
table-2-selected -> table-5-randomiz

Table 2 Selected large series of LDP and RADP
Table 2 Serum free T4:free T3 ratios in treated hypothyroid patients
Table 2. Set of reference peptide for retention time correction
Table 2 Sexual function and fertility in adults treated for PUV in childhood
Table 2 SLC2A9 , ABCG2 and SLC22A12 variants associated
Table 2 Spermatozoal damage caused by STDs
Table 2 Stimuli of MV release relevant for liver diseases
Table 2 Studies comparing HER2 status in the primary tumour and in CTCs
Table 2 Studies correlating ultrastructural findings with DUA or urinary retention
Table 2 Studies investigating the symptoms of GUTB*
Table 2 Studies of rituximab treatment in MMN
Table 2 Studies of salt restriction in patients with CKD
Table 2 Studies of the VEGF pathway as a predictive marker in breast cancer
Table 2 Studies of VUR in patients with or without BBD since 2008
Table 2 Summary of methods for generating pluripotent stem cells
Table 2: Summary of Sample Selection and Exclusions
Table 2 - Summary of WWEC operating treatment plants characteristics (2010)
Table 2 The extent of lymphadenectomy
Table 2 Therapeutic agents used to maintain remission in patients with ANCA-associated vasculitis
Table 2 Therapeutic role of regional LND for UTUC in pN0, pN+, and pNx patients
Table 2 Top five most prevalent ‘rare’ aetiologies for stroke in young Western populations
Table 2. Top Networks Involved.
Table 2 Unsuccessful or terminated phase III trials with anti‑VEGF pathway agents
Table 2 Within-reader and between-reader reproducibility for all MRI parameters, by vessel
Table 22-2 Page 493
Table 23.1
Table 24-1
Table 24 Ext 162 Erlis
Table 27-3 A Review of Important Terms Relating to Acid–Base Balance
Table 2S
Table 3:
Table 3.1.1: Stock and Flow of Heart Transplantation, 1997-2005
Table 3.1 Body Fluids
Table 3.1 List of the tropical cyclones reaching TS intensity or higher in 2011
Table 3.1 List of the tropical cyclones reaching TS intensity or higher in 2011
Table 3: 5’ upstream cis -regulatory motif
Table 3 Adjuvant anthracycline criteria based upon anthracycline ‘strength’
Table 3 ANKH mutations associated with CPPD
Table 3: Association between renal failure and Chinese herbs exposure
Table 3 Clinical trial of venous thromboembolism prophylaxis in cancer patients using CVCs
Table 3 Deregulated miRNAs, targets and potential functions in gastric cancer
TABLE 3 Developmental Trends Observed and Predicted On Different Problem-Types in Experiment 1 a
TABLE 3 Developmental Trends Observed and Predicted On Different Problem-Types in Experiment 1 a
Table 3 Disease prevalence in patients evaluated initially with US and IVU
Table 3 Effects of approved treatments on BMD and incident vertebral fractures in GIOP RCTs
Table 3 Final Wellness Presentation
Table 3. FPRL1 use and amino acid sequences of the V3 loop for HIV-1 strains and isolates.
Table 3 Immunotherapy in clinical trials for glioblastoma
Table 3 Incontinence quality of life questionnaire (I-QOL). 56
Table 3 Karnofsky performance status
Table 3 Ongoing clinical trials that study CTCs in breast cancer with therapeutic intervention
Table 3 Pharmacological conditioning in patients with STEMI undergoing PPCI
Table 3 Phase III trials of targeted agents in advanced pancreatic carcinoma
Table 3 Potential biomarkers associated with NPSLE
Table 3
Table 3 Relationship between biomarkers and RIFLE class or AKIN stage in adults
Table 3. Results from Constructed Wetland Treatment System Bird Surveys.
Table 3 Routine clinical follow-up after prosthetic AVR or MVR
Table 3. Seed yield traits for the F 2:7 RILs.
Table 3 Studies evaluating HRQL among survivors of AKI
Table 3 Studies investigating the affected organs and symptoms in women with GUTB
Table 3 Summary of infection-associated AILS cases
Table 3 Temporal changes in the 5 ‑ year stroke risk* in ACAS and ACST
Table 3 The effects of RYGB procedures on weight loss and resolution of T2DM
Table 3 Trials assessing the effect of dMMR on 5-FU-based treatment outcomes
Table 3 VEGF pathway‑targeted drugs currently in neoadjuvant clinical trials
Table 3:Yale Result
TABLE 32-3. -- Common Causes of Severe Community-Acquired Pneumonia* [†]
Table 355-2: Principal Classic Neurotransmitters
Table 4
TABLE 4.1
TABLE 4.1
Table 4.1.1: Stock and Flow of Liver Transplantation, 1993-2005
Table 4.1. A Skill Profile of Tomorrow s Workforce in Representative OECD countries.
Table 4-1. Value and Model Assumptions in Social Stratification Paradigms (from Kerbo, p. 87)
Table 4.2: Distribution of Inpatient vs. Outpatient Revenues, 1981 – 2005
Table 4.2: Distribution of Inpatient vs. Outpatient Revenues, 1981 – 2006
Table 4.2: Distribution of Inpatient vs. Outpatient Revenues, 1987 – 2007
Table 4.3 SSU & Peers
Table 4 Assessing the impact of dMMR on response to irinotecan
Table 4 Blockade of CTGF, EGF or PDGF pathways—adverse effects and hypothetical threats
Table 4:Correlations of Narratives with other Measures of Parenting
Table 4 Diagnosis at 6-month to 1-year follow-up in early arthritis cohorts
Table 4: Implications for the learner Are reformed curricula, pedagogies etc leading to changes in learners’ performanc
Table 4 Neurophysiological abnormalities in the proprioceptive sensory domain in PD
Table 4 Ongoing phase III trials in patients with pancreatic carcinoma
Table 4. Parameters of the Cox Equation. T b A o 10 3 A 1 10 6 A 2
Table 4 presentation
Table 4 Pulse cyclophosphamide reduction based on renal function and age
Table 4 Results of SBRT for liver metastasis from selected studies
Table 4. クラインフェルター症候群患者の妊孕性温存 ( Rives N, et al. Human Reproduction 28: 1468-1479, 2013 .)
Table 4 Selected trials of antihypertensive treatment in elderly patients
Table 4 VHL alterations as potential predictive markers
Table 4A
TABLE 4A – TRAINING (DAY)
Table 5.1.1: Stock and Flow of Renal Transplantation, 1996-2005
Table 5.1.1: Stock and Flow of Renal Transplantation, 1997-2006
Table 5-1. Kerbo’s Chapter 5 Outline: Modern (U.S.) Stratification Theories
Table 5-1
Table 5-1: Secondary-Data Sources
Table 5.1 The Estimated Size of U.S. Manufactured Capital Stock
Table 5.1 The UP3core Functions.
Table 5.5 The COMPUTE Instruction
Table 5 Linear Regression Results for First-Year Cumulative GPA

English
Français

About
Privacy
DMCA
Blog
Contact

© 2026 SlideServe. All rights reserved.